相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes
Koji Sasaki et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review
Priyanka Singh et al.
MEDICAL ONCOLOGY (2021)
Lonafarnib: First Approval
Sohita Dhillon
DRUGS (2021)
Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021
Tariq I. Mughal et al.
HAEMATOLOGICA (2021)
PKC-β/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia
Dan Ma et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2021)
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Valentin Garcia-Gutierrez et al.
BLOOD CANCER JOURNAL (2021)
Third-line therapy for chronic myeloid leukemia: current status and future directions
Jorge Cortes et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
Ya-Ching Hsieh et al.
LEUKEMIA (2021)
Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation
Hui Mu et al.
FRONTIERS IN ONCOLOGY (2021)
Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells
Sylwester Glowacki et al.
BIOMOLECULES (2021)
A Machine Learning Model to Successfully Predict Future Diagnosis of Chronic Myelogenous Leukemia With Retrospective Electronic Health Records Data
Ronald G. Hauser et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2021)
Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
Meike Kaehler et al.
FRONTIERS IN PHARMACOLOGY (2021)
Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review
P. Torres-Barrera et al.
CURRENT RESEARCH IN TRANSLATIONAL MEDICINE (2021)
Treatment-Free Remission-A New Aim in the Treatment of Chronic Myeloid Leukemia
Paulina Kwasnik et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
Daniel J. Klionsky et al.
AUTOPHAGY (2021)
Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia
Jean-Michel Cayuela et al.
BULLETIN DU CANCER (2020)
Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations
Michael J. Reff et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)
The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia
Hui Xu et al.
LEUKEMIA & LYMPHOMA (2020)
Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia
Manon Lernoux et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study
Zachariah DeFilipp et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
Simona Soverini et al.
BLOOD (2020)
Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications
Paula Sabbo Bernardo et al.
BLOOD REVIEWS (2020)
DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia
Henning D. Popp et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance
Zi-Yuan Nie et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells
Seda Baykal-Kose et al.
PLOS ONE (2020)
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
Abhishek Maiti et al.
ACTA HAEMATOLOGICA (2020)
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia
Tun Kiat Ko et al.
BLOOD (2020)
Response and Resistance to BCR-ABL1-Targeted Therapies
Theodore P. Braun et al.
CANCER CELL (2020)
Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors
Katharina Rothe et al.
CELL STEM CELL (2020)
A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies.
Maro Ohanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
Andreas Hochhaus et al.
LEUKEMIA (2020)
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Rahul Kumar et al.
LEUKEMIA (2020)
Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
Cosimo Cumbo et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes
Jan Stetka et al.
CANCERS (2020)
Mining Drug-Target Associations in Cancer: Analysis of Gene Expression and Drug Activity Correlations
Monica M. Arroyo et al.
BIOMOLECULES (2020)
MDM2 inhibition: an important step forward in cancer therapy
Marina Konopleva et al.
LEUKEMIA (2020)
Chronic Myeloid Leukemia, Version 2.2021
Michael W. Deininger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Exosomes from Bone Marrow Microenvironment-Derived Mesenchymal Stem Cells Affect CML Cells Growth and Promote Drug Resistance to Tyrosine Kinase Inhibitors
Xiaoyan Zhang et al.
STEM CELLS INTERNATIONAL (2020)
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
Simona Soverini et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay
Hee-Jung Chung et al.
ANNALS OF LABORATORY MEDICINE (2020)
Targeting quiescent leukemic stem cells using second generation autophagy inhibitors
Pablo Baquero et al.
LEUKEMIA (2019)
Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells
Puneet Agarwal et al.
CELL STEM CELL (2019)
Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia
Raquel Alves et al.
MEDICAL ONCOLOGY (2019)
Impact of Additional Chromosomal Aberrations on the Disease Progression of Chronic Myelogenous Leukemia
Ramachandran Krishna Chandran et al.
FRONTIERS IN ONCOLOGY (2019)
Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options
Daniel Nisakar Meenakshi Sundaram et al.
DRUG DISCOVERY TODAY (2019)
Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms
Bruno A. Cardoso et al.
EXPERIMENTAL HEMATOLOGY (2019)
PF-114, a novel selective inhibitor of BCR-ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells
Ekaterina S. Ivanova et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA
Justin T. Brown et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2019)
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
Aytug Kizilors et al.
LANCET HAEMATOLOGY (2019)
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells
Ajay Abraham et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL
Jiu-Yu Zhan et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2019)
MicroRNA signature refine response prediction in CML
Raquel Alves et al.
SCIENTIFIC REPORTS (2019)
Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
Ipsita Pal et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
Christopher A. Eide et al.
CANCER CELL (2019)
ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
Dongqing Yan et al.
CLINICAL CANCER RESEARCH (2019)
Machine learning applications in the diagnosis of leukemia: Current trends and future directions
Haneen T. Salah et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2019)
The FoxO-Autophagy Axis in Health and Disease
Zhiyong Cheng
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2019)
Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors
Marjan Yaghmaie et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
Peter E. Westerweel et al.
FRONTIERS IN ONCOLOGY (2019)
Metabolic dependencies and vulnerabilities in leukemia
Marissa Rashkovan et al.
GENES & DEVELOPMENT (2019)
Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia
Fabien Muselli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Treatment-free remission with first- and second-generation tyrosine kinase inhibitors
Jorge Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors
Xuechao Liu et al.
CELL AND BIOSCIENCE (2019)
The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy
Tatjana Bilich et al.
BLOOD (2019)
Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making
Simona Soverini et al.
BLOOD (2019)
Nilotinib in the treatment of chronic myeloid leukemia
Tomasz Sacha et al.
FUTURE ONCOLOGY (2019)
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
Luana Bavaro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance
Vivek Kumar Singh et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2019)
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
Simona Soverini et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Fiona H. Tan et al.
ONCOTARGETS AND THERAPY (2019)
The research progress of circular RNAs in hematological malignancies
Tingting Ji et al.
HEMATOLOGY (2019)
Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon
Alan Rodrigues Andrade et al.
HEMATOLOGY TRANSFUSION AND CELL THERAPY (2019)
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease
Sanjay K. Nigam
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58 (2018)
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
Susan Branford et al.
BLOOD (2018)
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial
Sebastien Rinaldetti et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium
Sook Wah Yee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Venetoclax: A new wave in hematooncology
Jana Mihalyova et al.
EXPERIMENTAL HEMATOLOGY (2018)
The bone marrow microenvironment in health and disease at a glance
Rahul Kumar et al.
JOURNAL OF CELL SCIENCE (2018)
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Federico Rossari et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML
Oscar Bruck et al.
LEUKEMIA (2018)
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Michele Massimino et al.
MOLECULAR CANCER (2018)
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
Simona Soverini et al.
MOLECULAR CANCER (2018)
Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
Raquel C. Maia et al.
MOLECULES (2018)
ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
Laura N. Eadie et al.
PLOS ONE (2018)
A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia
Su-In Lee et al.
NATURE COMMUNICATIONS (2018)
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
Laura N. Eadie et al.
Oncotarget (2018)
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
Elena Arrigoni et al.
STEM CELLS TRANSLATIONAL MEDICINE (2018)
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial
Maro Ohanian et al.
LANCET HAEMATOLOGY (2018)
Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia
Sabrina Inselmann et al.
CANCER RESEARCH (2018)
Polymorphisms of the Multidrug Pump ABCG2: A Systematic Review of Their Effect on Protein Expression, Function, and Drug Pharmacokinetics
Niall Heyes et al.
DRUG METABOLISM AND DISPOSITION (2018)
BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia
Klara Srutova et al.
HAEMATOLOGICA (2018)
Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients
Siti Maziras Makhtar et al.
JOURNAL OF GENETICS (2018)
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Joseph Schoepfer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
Kendra Sweet et al.
LEUKEMIA RESEARCH (2018)
Mathematical modeling and computational prediction of cancer drug resistance
Xiaoqiang Sun et al.
BRIEFINGS IN BIOINFORMATICS (2018)
The roles of DNA epigenetics and clinical significance in Chronic Myeloid Leukemia: a review
Aliasghar Keramatinia et al.
CELLULAR AND MOLECULAR BIOLOGY (2018)
Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy
TaeHyung Kim et al.
BLOOD (2017)
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
Philippe Rousselot et al.
CANCER (2017)
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
L. N. Eadie et al.
LEUKEMIA (2017)
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
Juan Eduardo Megias-Vericat et al.
LEUKEMIA & LYMPHOMA (2017)
Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
Giovanni Luca Beretta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
Ami B. Patel et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Epigenetic dysregulation of hematopoietic stem cells and preleukemic state
Hiroyoshi Kunimoto et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia
Naofumi Mukaida et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
Ziyuan Lu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo
H. Zhou et al.
LEUKEMIA (2017)
Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia
Ayuna Hattori et al.
NATURE (2017)
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
Andrew A. Wylie et al.
NATURE (2017)
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
Elodie M. Kuntz et al.
NATURE MEDICINE (2017)
Remembrance of things past-discontinuation of second-generation TKI therapy for CML
Timothy P. Hughes et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis
Zhi-Ping Jiang et al.
PHARMACOGENOMICS (2017)
Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
E. Togasaki et al.
BLOOD CANCER JOURNAL (2017)
Intelligent Techniques Using Molecular Data Analysis in Leukaemia: An Opportunity for Personalized Medicine Support System
Haneen Banjar et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
Amy Hughes et al.
FRONTIERS IN IMMUNOLOGY (2017)
Preliminary data on microRNA expression profiles in a group of South African patients diagnosed with chronic myeloid leukaemia
Andrea Prinsloo et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update
Ahmet Emre Eskazan et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2017)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Hochhaus et al.
ANNALS OF ONCOLOGY (2017)
Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches
Emilie Cayssials et al.
BIODRUGS (2017)
hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia
Islem Ben Hassine et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Tessa L. Holyoake et al.
BLOOD (2017)
Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The C421A (Q141K) polymorphism enhances the 3′-untranslated region (3′-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2
Anne Ripperger et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Somatic mosaicism in chronic myeloid leukemia in remission
Kinuko Mitani et al.
BLOOD (2016)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
miR-146b-5p within BCR-ABL1-Positive Microvesicles Promotes Leukemic Transformation of Hematopoietic Cells
Hong-Mei Zhang et al.
CANCER RESEARCH (2016)
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Jamie I. Fletcher et al.
DRUG RESISTANCE UPDATES (2016)
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
Lisa Pleyer et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
M. Wagle et al.
LEUKEMIA (2016)
Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL135INS
Ellin Berman et al.
LEUKEMIA RESEARCH (2016)
Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice
Flavia da Cunha Vasconcelos et al.
LEUKEMIA RESEARCH (2016)
MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells
Tsung-Yao Lin et al.
PLOS ONE (2016)
Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation
Yuki Taya et al.
SCIENCE (2016)
Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
Claudia Neul et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
S. Harrach et al.
BLOOD CANCER JOURNAL (2016)
MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia
Chiranjib Chakraborty et al.
ONCOTARGET (2016)
Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells
S. Agatheeswaran et al.
SCIENTIFIC REPORTS (2016)
Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
David A. Irvine et al.
SCIENTIFIC REPORTS (2016)
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Lauren Caldemeyer et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines
Laura N. Eadie et al.
PLOS ONE (2016)
The Philadelphia chromosome in leukemogenesis
Zhi-Jie Kang et al.
CHINESE JOURNAL OF CANCER (2016)
The multifaceted roles of fatty acid synthesis in cancer
Florian Roehrig et al.
NATURE REVIEWS CANCER (2016)
Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells
Seiichi Okabe et al.
BLOOD (2016)
Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
N. Ader I. Al-Dewik et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2016)
Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors
Wei Wang et al.
BLOOD (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
The dynamics of adult haematopoiesis in the bone and bone marrow environment
Miriel S. H. Ho et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia
Shantashri Vaidya et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML)
Silvia Marce et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2015)
The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia
Fatima Dkhissi et al.
EXPERIMENTAL HEMATOLOGY (2015)
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
Marialuisa Polillo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
OCT1 and imatinib transport in CML: is it clinically relevant?
D. B. Watkins et al.
LEUKEMIA (2015)
Drug transporters play a key role in the complex process of Imatinib resistance in vitro
Raquel Alves et al.
LEUKEMIA RESEARCH (2015)
Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
Gregor Hoermann et al.
MEDIATORS OF INFLAMMATION (2015)
Structure and function of Gab2 and its role in cancer (Review)
Chen-Bo Ding et al.
MOLECULAR MEDICINE REPORTS (2015)
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
Stephane Prost et al.
NATURE (2015)
Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells
Kazuhito Naka et al.
NATURE COMMUNICATIONS (2015)
The physiological role of drug transporters
Yu Liang et al.
PROTEIN & CELL (2015)
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph plus ) leukemias harboring the T315I mutation
A. A. Mian et al.
LEUKEMIA (2015)
Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
Shantashri Vaidya et al.
PLOS ONE (2015)
Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review
E. V. Morozova et al.
BIOMARKER INSIGHTS (2015)
Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib
Janusz Blasiak et al.
BIORESEARCH OPEN ACCESS (2015)
Epigenetic drugs against cancer: an evolving landscape
Antonella Di Costanzo et al.
ARCHIVES OF TOXICOLOGY (2014)
Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients
Anthony Au et al.
BIOMEDICINE & PHARMACOTHERAPY (2014)
ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance
A. F. Ferreira et al.
BLOOD CELLS MOLECULES AND DISEASES (2014)
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Matthew S. Zabriskie et al.
CANCER CELL (2014)
Structure, Function, and Resistance in Chronic Myeloid Leukemia
Jerald Radich
CANCER CELL (2014)
Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation
Paulina Podszywalow-Bartnicka et al.
CELL CYCLE (2014)
Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia
Varsha Gandhi et al.
CLINICAL CANCER RESEARCH (2014)
Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib
L. N. Eadie et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy
Siham Bibi et al.
HAEMATOLOGICA (2014)
Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival
Yaoyu Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells
M. Nieborowska-Skorska et al.
LEUKEMIA (2014)
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status
M. Schmidt et al.
LEUKEMIA (2014)
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
Simona Soverini et al.
LEUKEMIA RESEARCH (2014)
Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia
Luciene Terezina de Lima et al.
MEDICAL ONCOLOGY (2014)
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia
Leyuan Ma et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
Anne Y. Saiki et al.
ONCOTARGET (2014)
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
J. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
Kimberly Cramer-Morales et al.
BLOOD (2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Andreas Hochhaus et al.
BLOOD (2013)
JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia
Wolfgang Warsch et al.
BLOOD (2013)
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling
Bin Zhang et al.
BLOOD (2013)
Myeloproliferative Neoplasia Remodels the Endosteal Bone Marrow Niche into a Self-Reinforcing Leukemic Niche
Koen Schepers et al.
CELL STEM CELL (2013)
BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability
A. Slupianek et al.
LEUKEMIA (2013)
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors
F. U. Woehrle et al.
LEUKEMIA (2013)
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
Ellen K. Ritchie et al.
LEUKEMIA & LYMPHOMA (2013)
Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias
L. A. Tobin et al.
ONCOGENE (2013)
Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
Lisa Christiansson et al.
PLOS ONE (2013)
Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation
M. Sigl et al.
BLOOD CANCER JOURNAL (2013)
Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies
Wesam Ahmed et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Role of Epigenetics in Chronic Myeloid Leukemia
Katerina Machova Polakova et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
Sara Redaelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Drug Transporters in Drug Efficacy and Toxicity
M. K. DeGorter et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Hagop M. Kantarjian et al.
BLOOD (2012)
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
Jorge Cortes et al.
BLOOD (2012)
HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells
Haojian Zhang et al.
BLOOD (2012)
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
Xuelin Huang et al.
CANCER (2012)
Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
Florian H. Heidel et al.
CELL STEM CELL (2012)
Bone Marrow Microenvironment in Multiple Myeloma Progression
S. Manier et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells
Joana Dinis et al.
LEUKEMIA & LYMPHOMA (2012)
Autophagy modulation as a potential therapeutic target for diverse diseases
David C. Rubinsztein et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Sirtuins as regulators of metabolism and healthspan
Riekelt H. Houtkooper et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Genetic Mechanisms of Chronic Myeloid Leukemia Blastic Transformation
Tomasz Skorski
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2012)
Role of STAT3 in transformation and drug resistance in CML
Rajesh R. Nair et al.
FRONTIERS IN ONCOLOGY (2012)
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
Alice Fabarius et al.
BLOOD (2011)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini et al.
BLOOD (2011)
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
Wolfgang Warsch et al.
BLOOD (2011)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes et al.
BLOOD (2011)
BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP
Daniela Salles et al.
CARCINOGENESIS (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
Sagar Agarwal et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Epigenetic inactivation of the hsa-miR-203 in haematological malignancies
Chor Sang Chim et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
Targeting PKC-Mediated Signal Transduction Pathways Using Enzastaurin to Promote Apoptosis in Acute Myeloid Leukemia-Derived Cell Lines and Blast Cells
Peter P. Ruvolo et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
Hilmar Quentmeier et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Expression patterns of microRNAs associated with CML phases and their disease related targets
Katerina Machova Polakova et al.
MOLECULAR CANCER (2011)
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases
V. Grossmann et al.
LEUKEMIA (2011)
Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state
Tomasz Skorski
LEUKEMIA & LYMPHOMA (2011)
Mechanisms of resistance to BCR--ABL kinase inhibitors
Joana M. Diamond et al.
LEUKEMIA & LYMPHOMA (2011)
Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed
Lina Eliasson et al.
LEUKEMIA RESEARCH (2011)
Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale
J. T. Brown et al.
BLOOD CANCER JOURNAL (2011)
MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML
Sukanya Suresh et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2011)
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
Daniel W. Sherbenou et al.
BLOOD (2010)
Immunotherapy of chronic myeloid leukemia: present state and future prospects
Vladimir Vonka
IMMUNOTHERAPY (2010)
Deactylase inhibition in myeloproliferative neoplasms
Sridurga Mithraprabhu et al.
INVESTIGATIONAL NEW DRUGS (2010)
Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group
Torsten Haferlach et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers
Thomas Dunwell et al.
MOLECULAR CANCER (2010)
Expression of Oncogenic Kinase Bcr-Abl Impairs Mitotic Checkpoint and Promotes Aberrant Divisions and Resistance to Microtubule-Targeting Agents
Kamila Wolanin et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia
Hugues de Lavallade et al.
LEUKEMIA RESEARCH (2010)
TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Kazuhito Naka et al.
NATURE (2010)
Dasatinib in chronic myeloid leukemia: a review
Apostolia-Maria Tsimberidou
Therapeutics and Clinical Risk Management (2010)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Lucien Noens et al.
BLOOD (2009)
Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
Sabine Mumprecht et al.
BLOOD (2009)
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
C. Hegedus et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia
Dong Hwan (Dennis) Kim et al.
CLINICAL CANCER RESEARCH (2009)
Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
Dong Bai et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells
Cristian Bellodi et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Methylation status of RASSF1A in patients with chronic myeloid leukemia
Antigoni Avramouli et al.
LEUKEMIA RESEARCH (2009)
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
Yaoyu Chen et al.
NATURE GENETICS (2009)
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia
Athina Giannoudis et al.
BLOOD (2008)
Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair
Annahita Sallmyr et al.
CANCER LETTERS (2008)
BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair
Kimberly Cramer et al.
CANCER RESEARCH (2008)
Interaction of imatinib with human organic ion carriers
Shuiying Hu et al.
CLINICAL CANCER RESEARCH (2008)
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications
Devendra K. Hiwase et al.
CLINICAL CANCER RESEARCH (2008)
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance
Mark B. Meads et al.
CLINICAL CANCER RESEARCH (2008)
P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2008)
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
Nadine N. Bewry et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
Shaoguang Li
LEUKEMIA & LYMPHOMA (2008)
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
Deborah L. White et al.
BLOOD (2007)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
Jorge Cortes et al.
CANCER (2007)
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib
Jorge Cortes et al.
CANCER (2007)
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia
Yasuhiro Oki et al.
CANCER (2007)
Treatment interruptions and non-adherence with imatinib and associated healthcare costs - A retrospective analysis among managed care patients with chronic myelogenous leukaemia
Theodore Darkow et al.
PHARMACOECONOMICS (2007)
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
Miriam Puttini et al.
CANCER RESEARCH (2006)
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Karen W. L. Yee et al.
CLINICAL CANCER RESEARCH (2006)
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients
O. Frank et al.
LEUKEMIA (2006)
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
Mateusz Koptyra et al.
BLOOD (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells
BZ Carter et al.
BLOOD (2006)
Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach
R. Villuendas et al.
LEUKEMIA (2006)
Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex
S Rampalli et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
A Burchert et al.
LEUKEMIA (2005)
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
JPJ Issa et al.
BLOOD (2004)
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias
S Zhao et al.
LEUKEMIA (2004)
BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks
MO Nowicki et al.
BLOOD (2004)
ABCG2 -: a transporter for all seasons
B Sarkadi et al.
FEBS LETTERS (2004)
Src family kinases, key regulators of signal transduction
SJ Parsons et al.
ONCOGENE (2004)
p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation
Y Canitrot et al.
BLOOD (2003)
Results of decitabine (5-Aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia
HM Kantarjian et al.
CANCER (2003)
Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells
E Deutsch et al.
BLOOD (2003)
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxarmic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells
R Nimmanapalli et al.
BLOOD (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate
AJ Tipping et al.
EXPERIMENTAL HEMATOLOGY (2003)
Imatinib: a selective tyrosine kinase inhibitor
PW Manley et al.
EUROPEAN JOURNAL OF CANCER (2002)
Drug therapy: Imatinib mesylate - A new oral targeted therapy.
DG Savage et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype
S Zhou et al.
NATURE MEDICINE (2001)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies
LA Hazlehurst et al.
CANCER AND METASTASIS REVIEWS (2001)
Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia:: biological implications
TT Nguyen et al.
BLOOD (2000)
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
BJ Druker et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
